Prof. James CS Chim
Department of Medicine
University of Hong Kong, China
Professor
Email: jcschim@hku.hk
Qualifications
2011 Founding Fellow, Faculty of Science, the Royal College of Pathologists of Australia
2006 Ph.D., Philosophy
Publications (Selected)
-
Tang HKK, Fung CY, Hwang YY, Lee H, Lau G, Yip SF, Kho B, Lau CK, Leung KH, Au E, Tse E, Sim J, Kwong YL, Chim CS. Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM. Bone Marrow Transplant. 2024 May;59(5):660-669.
-
Ip BBK, Wong ATC, Law JHY, Au CH, Ma SY, Chim JCS, Liang RHS, Leung AYH, Wan TSK, Ma ESK. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. Sci Rep. 2024 Mar 16;14(1):6400.
-
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Lin TL, Chim CS, Qi M, Wang J, Lu X, Song Y, Jia B, Yang X, Liu W, Zhou T, Yin L, Li Y, Zhang R, Hou J, Wang J. Clin. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study. Lymphoma Myeloma Leuk. 2023 Jun;23(6):446-455.e4.
-
Zhang MY, Calin G, Deng MD, Au-Yeung RKH, Wang LQ, Chim CS. Epigenetic Silencing of Tumor Suppressor lncRNA NKILA: Implication on NF-κB Signaling in Non-Hodgkin's Lymphoma. Genes (Basel). 2022 Jan 11;13(1):128. doi: 10.3390/genes13010128.
-
Chim CS, Kumar S, Wong VKC, Ngai C, Kwong YL. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. Hematology. 2021 Dec;26(1):652-655.
-
Cheong Ngai, Shaji Kumar, Garrett Chi-lai Ho, Sirong Chen, Chor-sang Chim. MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma. Therapeutic Advances in Hematology, 2021 Sep 30; 12: 20406207211030369 (IF: 7.167)
-
Min Yue Zhang; George Calin; Kit San Yuen; Dong Yan Jin; Chor Sang Chim. Epigenetic silencing of miR-342-3p in B-cell lymphoma and its impact on autophagy. Clinical Epigenetics 2020 Oct 19;12(1):150. (IF: 6.551)
-
Soekojo, C.Y., Kim, K., Huang, SY., Chim, C. S. et al. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network. Blood Cancer J. 9, 83 (2019). https://doi.org/10.1038/s41408-019-0245-1
-
Bai, Y., & Chim, C. S. (2019). Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma. Hematology, 24(1), 533–537. https://doi.org/10.1080/16078454.2019.1637574
-
Yao Q, Bai Y, Orfao A and Chim CS (2019) Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Front. Oncol. 9:449. doi: 10.3389/fonc.2019.00449
-
Yinlei Bai, Alberto Orfao, Chor Sang Chim. Molecular Detection of Minimal Residual Disease in Multiple Myeloma. Br J Haematol. 2018 Apr;181(1):11-26. (IF: 6.998)
-
Yao, Q., Morgan, G.J. & Chim, C.S. Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses. Clin Epigenet 10, 158 (2018). https://doi.org/10.1186/s13148-018-0597-6
-
Chan, T.S.Y., Au-Yeung, R., Chim, CS. et al. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann Hematol 96, 871–872 (2017). https://doi.org/10.1007/s00277-017-2944-7
-
Qian Wang L., Yeung Wong K., Hai Li Z., Sang Chim C. Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. Oncotarget. 2016; 7: 82400-82410. Retrieved from https://www.oncotarget.com/article/12252/text/
-
Wang L. Qian, Wong K. Yeung, Rosèn A., Chim C. Sang Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget. 2015; 6: 44422-44436. Retrieved from https://www.oncotarget.com/article/6251/text/
-
Wong, K. Y., & Chim, C. S. (2015). DNA Methylation of Tumor Suppressor Protein-Coding and Non-Coding Genes in Multiple Myeloma. Epigenomics, 7(6), 985–1001. https://doi.org/10.2217/epi.15.57
-
KY Wong, Rita LH Yim, CC So, DY Jin, Raymond Liang, Chim CS. Epigenetic
inactivation of the MIR34B/C in multiple myeloma. Blood 2011;
118: 5901-5904.
-
ChimCS, KY Wong, Y Qi, Loong F, WL Lam, LG Wong, Jin
DY, Costello JF, Liang R. Epigenetic inactivation of the miR-34a in
hematological malignancies. Carcinogenesis, 2010, 31(4):745-50.
-
Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic
Dysregulation of Wnt Signaling Pathway in Multiple Myeloma. Leukemia; 21(12): 2527-36, 2007.
-
Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF,
Kwong YL. Aberrant promoter methylation of the retinoic acid receptor
alpha gene in acute promyelocytic leukemia. Leukemia. 2005
Dec;19(12):2241-6.
-
Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG,
Kho BC, Lee HK, Sim JP, Chan CH, Chan JC, Yeung YM, Law M, Liang R.Long-term
outcome of 231 patients with Essential Thrombocythemia: Prognostic factors
for bleeding, thrombosis, myelofibrosis and leukaemia. Archives Int
Med, 2005, 165: 2651-2658.
-
Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau
CC, Kwong YL. Primary nasal natural killer cell lymphoma: long-term
treatment outcome and relationship with the International Prognostic
Index. Blood 2004, 103: 216-221.
-
Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL.SOCS1
and SHP1 Hypermethylation in Multiple Myeloma: Implications for Epigenetic
Activation of the Jak/STAT pathway. Blood2004; 103: 4630-4635.
-
Chim CS, Liang R, Tam CY, Kwong YL. Methylation of
p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic
and prognostic significance. J Clin Oncol, 19: 2033-2040, 2001.
Personal Profile
https://loop.frontiersin.org/people/36170/overview
https://orcid.org/0000-0003-2427-915X
https://scholars.croucher.org.hk/scholars/james-chim